Adaptimmune Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADAP and other ETFs, options, and stocks.

About ADAP

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

CEO

Adrian Rawcliffe

CEOAdrian Rawcliffe

Employees

494

Employees494

Headquarters

Abingdon, Oxfordshire

HeadquartersAbingdon, Oxfordshire

Founded

2014

Founded2014

Employees

494

Employees494

ADAP Key Statistics

Market cap

175.00M

Market cap175.00M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

480.06K

Average volume480.06K

High today

$1.09

High today$1.09

Low today

$1.01

Low today$1.01

Open price

$1.08

Open price$1.08

Volume

226.54K

Volume226.54K

52 Week high

$5.95

52 Week high$5.95

52 Week low

$1.01

52 Week low$1.01

Analyst ratings

57%

of 7 ratings

Buy

28.6%

Hold

57.1%

Sell

14.3%

ADAP Earnings

-$0.30

-$0.15

-$0.01

$0.14

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Nov 3, Pre-Market

ActualExpected Nov 3, Pre-Market